Molecular genetics, imaging and treatment of oligodendroglial tumours

Michael D Jenkinson; Carol Walker; Andrew R Brodbelt; Simone Wilkins; David Husband; Brian Haylock

doi:10.1007/s00701-010-0784-5

Molecular genetics, imaging and treatment of oligodendroglial tumours

Acta Neurochir (Wien). 2010 Nov;152(11):1815-25. doi: 10.1007/s00701-010-0784-5. Epub 2010 Sep 2.

Authors

Michael D Jenkinson¹, Carol Walker, Andrew R Brodbelt, Simone Wilkins, David Husband, Brian Haylock

Affiliation

¹ Department of Neurosurgery, The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, L9 7LJ, UK. michael.jenkinson@liv.ac.uk

PMID: 20811757
DOI: 10.1007/s00701-010-0784-5

Abstract

The discovery of a genetic signature of chemosensitivity and prognosis in oligodendroglial tumours prompted a new optimism in glioma management. After more than a decade since the initial reports, where do we stand in the current management of oligodendroglial tumours? This review focuses on the latest molecular genetics, imaging characteristics, and recent trials of treatment paradigms for these tumours.

Publication types

Review

MeSH terms

Antineoplastic Protocols / standards
Brain / pathology*
Brain / physiopathology
Brain Neoplasms / diagnosis*
Brain Neoplasms / genetics*
Brain Neoplasms / therapy
Combined Modality Therapy / methods
Combined Modality Therapy / trends
Diagnostic Imaging / methods
Diagnostic Imaging / trends
Genetic Predisposition to Disease / genetics*
Humans
Molecular Biology / methods
Molecular Biology / trends
Oligodendroglioma / diagnosis*
Oligodendroglioma / genetics*
Oligodendroglioma / therapy
Prognosis
Survival Rate / trends